Effect of microaneurysms on the anti-VEGF treatment for diabetic macular edema: A retrospective cross-sectional study

Akira Watanabe1, Hirotugu Takashina2, Tadashi Nakano1

  • 1Department of Ophthalmology, The Jikei University School of Medicine, Tokyo, Japan.

Medicine
|November 7, 2023
PubMed

Insights

Microaneurysm (MA) status impacts anti-vascular endothelial growth factor (VEGF) treatment for diabetic macular edema (DME). More MAs and leaking MAs reduce treatment effectiveness, indicating a need for personalized therapeutic strategies.

Area of Science:

  • Ophthalmology
  • Medical Research
  • Diabetic Retinopathy

Background:

  • Diabetic macular edema (DME) is a common complication of diabetes.
  • Anti-vascular endothelial growth factor (anti-VEGF) therapy is a primary treatment for DME.
  • The influence of microaneurysm (MA) characteristics on anti-VEGF treatment efficacy in DME is not fully understood.

Purpose of the Study:

  • To investigate the impact of microaneurysm (MA) number and leakage status on diabetic macular edema (DME).
  • To evaluate how MA characteristics affect the therapeutic efficacy of anti-vascular endothelial growth factor (anti-VEGF) treatment in DME patients.

Main Methods:

  • Retrospective analysis of 51 eyes from 47 DME patients undergoing anti-VEGF treatment.
  • Fluorescence angiography to quantify MA number and leakage.
  • Optical coherence tomography (OCT) to assess retinal thickness.
  • Correlation analysis between MA status, retinal thickness, and treatment outcomes.

Main Results:

  • A significant correlation was found between the number of MAs and retinal thickness in both 6mm and 3mm sectors before and after anti-VEGF treatment.
  • Leaking MAs were associated with significantly greater retinal thickness compared to non-leaking MAs before and after treatment.
  • Anti-VEGF treatment showed reduced effectiveness in cases with a high number of MAs, particularly those with leakage.

Conclusions:

  • The degree of retinal edema in DME is associated with the number and leakage status of MAs.
  • Anti-VEGF therapy may be less effective for DME characterized by numerous MAs, especially those that are leaking.
  • MA status is a critical factor influencing DME treatment outcomes with anti-VEGF agents.